Cannabidiol/tetrahydrocannabinol - Intec Pharma

Drug Profile

Cannabidiol/tetrahydrocannabinol - Intec Pharma

Alternative Names: Accordion Pill- Cannabidiol/tetrahydrocannabinol; AP-CBD/THC; Tetrahydrocannabinol/cannabidiol - Intec Pharma

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intec Pharma
  • Class Analgesics; Antiemetics; Anxiolytics; Appetite stimulants; Cannabinoids; Muscle relaxants; Neuroprotectants; Phytotherapies
  • Mechanism of Action Cannabinoid receptor CB1 antagonists; Cannabinoid receptor CB2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Fibromyalgia; Pain

Most Recent Events

  • 15 Nov 2017 Intec Pharma plans a phase I pharmacokinetic trial of the revised Accordion pill cannabidiol/tetrahydrocannabinol
  • 09 Aug 2017 Intec Pharma completes a phase I trial in healthy volunteers in Israel
  • 03 Aug 2017 Pharmacokinetics and adverse events data from a phase I trial in Pain and Fibromyalgia (In volunteers) released by Intec Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top